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Repeated Measures of Blood and 
Breath Ammonia in Response to 
Control, Moderate and High Protein 
Dose in Healthy Men
Lisa A. Spacek1,6, Arthur Strzepka4, Saurabh Saha2, Jonathan Kotula2, Jeffrey Gelb2,  
Sarah Guilmain2, Terence Risby3 & Steven F. Solga4,5
Ammonia physiology is important to numerous disease states including urea cycle disorders and hepatic 
encephalopathy. However, many unknowns persist regarding the ammonia response to common and 
potentially significant physiologic influences, such as food. Our aim was to evaluate the dynamic range 
of ammonia in response to an oral protein challenge in healthy participants. We measured blood and 
breath ammonia at baseline and every hour for 5.5 hours. Healthy men (N = 22, aged 18 to 24 years) 
consumed a 60 g protein shake (high dose); a subset of 10 consumed a 30 g protein shake (moderate 
dose) and 12 consumed an electrolyte drink containing 0 g protein (control). Change in blood ammonia 
over time varied by dose (p = 0.001). Difference in blood ammonia was significant for control versus 
high (p = 0.0004) and moderate versus high (p = 0.03). Change in breath ammonia over time varied by 
dose (p < 0.0001). Difference in breath ammonia was significant for control versus moderate (p = 0.03) 
and control versus high (p = 0.0003). Changes in blood and breath ammonia were detectable by fast, 
minimally-invasive (blood) or non-invasive (breath) point-of-care ammonia measurement methods. 
These pilot data may contribute to understanding normal ammonia metabolism. Novel measurement 
methods may aid research into genetic and metabolic ammonia disorders.
Ammonia physiology is important to numerous disease states including genetic metabolic diseases, i.e., urea cycle 
disorders and hepatic encephalopathy amongst patients with cirrhosis1. The biochemical pathways of ammonia 
genesis and disposal are understood. However, the relative contributions of various organs and body compart-
ments including: the liver, the colon and its microbiome, the kidneys, muscle tissue, and small bowel enterocytes, 
to ammonia homeostasis is less well-defined. And, at the individual level, these knowledge gaps are magnified 
further. For example, basic information about the impact of a routine physiologic intervention, such as food 
consumption, is lacking.
These knowledge deficits impede clinical care. To illustrate using the common example of hepatic encepha-
lopathy, patients with cirrhosis were, for many years, instructed to consume a low-protein diet on the assumption 
that this would reduce ammonia genesis and mitigate encephalopathy2. More recently, however, expert guidelines 
recommend the opposite to prevent sarcopenia3. These knowledge deficits impair the evaluation of new putative 
ammonia lowering therapies.
Clinical research in ammonia physiology has been difficult because ammonia is very reactive and is challeng-
ing to measure. Venous ammonia is most commonly measured but the standard protocol is subject to multiple 
random and nonrandom errors (e.g., tourniquet time, sweat contamination, blood cell hemolysis, and delay in 
laboratory measurement)4. Furthermore, the requirement for phlebotomy diminishes enthusiasm for studies 
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requiring multiple samples. This is important because ammonia physiology, much like changes in blood glucose 
and many other metabolic processes, is dynamic.
Our aim was to evaluate the dynamics of the ammonia response to an oral protein challenge amongst healthy 
subjects. We hypothesized that ammonia would increase in a dose-dependent manner prior to returning to base-
line. We quantified blood ammonia serially in response to three protein doses: 0 g, 30 g, and 60 g. We used the 
PocketChem BA blood ammonia checker (Lancashire, United Kingdom); this is a portable handheld device that 
uses a small volume (20 µL) blood sample5. In tandem, we also measured exhaled breath ammonia. Though the 
measurement of systemic ammonia through exhaled breath has great potential, breath measurement research-
ers must contend with a group of novel challenges including: variability in breathing, contamination with oral 
mucosal or bacterial ammonia, influence of ambient air, instrument humidity, and temperature6. Recently, we 
found that 60 g of oral protein significantly increased breath ammonia amongst 30 healthy subjects compared to 
a negative control day7. We demonstrated for the first time that mouth exhaled breath ammonia reflects systemic 
ammonia and examined novel and important biology. However, the study lacked blood ammonia measurement.
To our knowledge, the present study is the first to evaluate the dynamic ammonia response to control, moder-
ate, and high oral protein doses and the first to do so using blood and breath ammonia measurement.
Results
Twenty-two participants were studied and provided samples of breath and blood ammonia. Participants ranged 
in age from 18 to 24 years and were all men. Mean body mass index (BMI) was 24.8 kg/m2 (SD, 2.2; range, 21.6–
31.6). Treatment groups included the control group (N = 12), moderate dose protein group (N = 10), and high 
dose protein group (N = 22). Mean blood ammonia ranged from 107 to 171 μg/dL at baseline and from 218 to 
342 μg/dL at maximum levels (Table 1). And, mean breath ammonia ranged from 490 to 704 ppb at baseline and 
from 920 to 1642 ppb at maximum.
Maximum concentrations (Cmax) of blood and breath ammonia by treatment groups (control, low dose, and 
high dose) are shown in Fig. 1a and b, respectively. Change from baseline over time in blood (Fig. 2a) and breath 
(Fig. 2b) ammonia varied by dose. Maximum levels for the high protein group occurred at 3 hours. Whereas 
maximum blood ammonia for the moderate protein group occurred at 2 hours, maximum breath ammonia for 
this group occurred at 4 hours.
Analysis of longitudinal data with a mixed model found that change in blood ammonia over time varied by 
dose (p = 0.001). Difference in blood ammonia was significant for control versus high (p = 0.0004) and moderate 
versus high (p = 0.03). As well, change in breath ammonia over time varied by dose (p < 0.0001). Difference in 
breath ammonia was significant for control versus moderate (p = 0.03) and control versus high (p = 0.0003).
Discussion
We have demonstrated that ammonia increased after a 60 g oral protein challenge. Furthermore, this increase was 
detectable by fast, minimally-invasive (blood) or non-invasive (breath) point-of-care ammonia measurement 
methods. These pilot data can facilitate and inspire future study in protein metabolism for numerous purposes. 
These findings are novel and important. Only a single study published over 40 years ago has previously reported 
on the systemic ammonia response to an oral protein8. We believe that the research effort in ammonia phys-
iology and protein metabolism has lagged at least in part because of the historical dependence on unreliable 
phlebotomy-based laboratory blood assays, and that our strategy offers new reason for optimism. Fast, minimal 
or non-invasive testing can help propel clinical research in cirrhosis, protein malnutrition and sarcopenia, hepatic 
encephalopathy, and pediatric urea cycle disorders.
Strengths of this study include different methods of measurement of ammonia over time and the compari-
son of ammonia levels in response to protein challenge. By measuring an individual’s response to a physiologic 
intervention, each individual serves as his or her own reference. Further, the measurement equipment is portable 
and offers real-time results. For example, we note that ammonia appears to increase toward the end of the testing 
period, even amongst the control group, which may be due to time of day influences previously described9. The 
connection between circadian clocks and metabolism may play a role. Recently, investigators found that short 
chain fatty acids directly modulate circadian clock gene expression within hepatocytes10.
Moreover, the relative tolerability of the measurements (i.e., lancet-derived blood samples and exhaled 
breath) enabled repeated measures within and across testing days. The tolerability of these tests, especially breath 
Control 
(N = 12)
Moderate protein 
(N = 10)
High protein 
(N = 22)
Blood Baseline Mean +/− SD 143 +/− 58 107 +/− 30 171 +/− 69
Median (IQR) 139 (95–194) 103 (85–126) 154 (112–212)
Maximum Mean +/− SD 218 +/− 82 232 +/− 84 342 +/− 87
Median (IQR) 205 (157–245) 199 (176–280) 368 (267–400)
Breath Baseline Mean +/− SD 585 +/− 291 490 +/− 208 704 +/− 372
Median (IQR) 682 (342–729) 514 (357–605) 625 (427–822)
Maximum Mean +/− SD 920 +/− 435 1107 +/− 543 1642 +/− 658
Median (IQR) 1022 (556–1277) 982 (676–1442) 1550 (1250–2156)
Table 1. Mean (+/−SD, standard deviation) and median (IQR, interquartile range) ammonia values for blood 
(μg/dL) and breath (ppb) at baseline and maximum by treatment group.
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measurement, may enable clinical study in an adult or pediatric population. Finally, our conclusions are strength-
ened by the general agreement in results based on two measurement modalities from different body compart-
ments (blood and breath).
Because of these assets, we can evaluate the hypothesis that oral protein increases systemic ammonia and 
outline its kinetics. This is important because even basic questions about food digestion and its relationship to 
ammonia metabolism remain unanswered. For example, a major recent review of ammonia metabolism11 cited 
five key papers on the impact of feeding on intestinal ammonia generation. Of these, 2 utilized animal mod-
els12,13, one utilized urinary protein measurement over multiple days and therefore could not assess the immediate 
impact of a food bolus14, and one was a small uncontrolled case series15. Only one article evaluated the response of 
blood ammonia and amino acid profiles to oral protein challenges in humans16. As demonstrated by our data, this 
study also found that, when an oral protein dose threshold was reached, systemic ammonia increased in healthy 
subjects and peaked 4 hours after ingestion.
Our study has limitations related to study design and study specifics. In that we evaluated the systemic ammo-
nia response to an oral protein challenge, we did not investigate the sources of ammonia. Ammonia metabolism 
is complex and fluid, and its influences are not well understood at any level (cellular, organ, or person)1. The liver, 
for example, both removes and produces ammonia in different physiologic compartments (i.e., zone 1 versus zone 
3 hepatocytes) under varying circumstances that remain poorly understood17. And, measuring specific organ flux 
is often highly invasive. For example, in a small study by Jalan et al., ammonia flux across the kidney was meas-
ured in multi-catheterized cirrhotic patients in response to a single challenge designed to simulate a gastrointes-
tinal bleed18. Similarly, landmark studies evaluating the portal venous contribution to systemic ammonia have 
used multi-catheterized animals that were subsequently euthanized19 or humans at laparotomy without a protein 
challenge20. Hence, while our study design resulted in inherent limitations, we note these trade-offs are ubiquitous 
in ammonia research and indeed hope that our emphasis on fast, easy, point-of-care tests using a physiologic 
challenge helps overcome future study design challenges.
Figure 1. (a) Maximum blood ammonia (μg/dL) for treatment groups: control, 30 g protein, and 60 g protein. 
Box and whisker plot includes: mean (diamond), median (solid line), and range. (b) Maximum breath ammonia 
(ppb) for treatment groups: control, 30 g protein, and 60 g protein. Box and whisker plot includes: mean 
(diamond), median (solid line), and range.
www.nature.com/scientificreports/
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We speculate that the increases in systemic ammonia after an oral challenge found in this study may include 
increased gut bacterial ammonia production, increased amino acid degradation with subsequent increased systemic 
glutamine leading to increased renal ammonia genesis, increased renal ammonia genesis due to transient acidosis, 
some combination of these factors, or other mechanisms. Additionally, the source of breath ammonia increase may 
be distinct from the source of blood ammonia increase. For example, breath ammonia may have increased due to 
increased blood urea leading to increased salivary urea and oral ammonia genesis21. Lastly, we also note that our 
prior work demonstrated that an ammonia increase to an oral protein intervention is temporally associated with 
increases in breath hydrogen and acetone; the former serves as a unique gut transit timing marker, and the latter 
indicates amino acid degradation7. Hence, through simultaneous multi-metabolite measurement, breath analysis 
offers the potential to create a distinctive and more complete metabolic picture than standard blood assays.
Other important limitations relate to our study specifics. Though our control and moderate oral protein challenges 
were the same fluid volume, the control intervention had fewer calories. The control intervention was not a placebo 
and could have contributed to metabolic changes. Also, to reduce variables in this pilot, we used only a single protein 
source. It is unknown, therefore, if these results are generalizable. Further, we note that, because breath and blood meas-
urements are both subject to significant variability and error, we did not find a significant correlation between them.
A final limitation is our use of only two ammonia measurement methods. There are multiple methods22 and 
testing platforms23 for measuring blood ammonia, and there have also been comparisons made between, for exam-
ple, venous versus arterial blood ammonia, partial pressure NH3 versus NH4+24,25. Moreover, no recognized refer-
ence method, material, or timing interval exists. Further, researchers are still evaluating various subject factors and 
pre-analytical effects which may influence blood ammonia determination and interject error such as concomitant 
vitamin K ingestion and alanine aminotransferase (ALT) or gamma-glutamyl transferase (GGT) levels26–28. In gen-
eral, however, the results of various ammonia measurement methodologies have been comparable under experi-
mental conditions. But, as noted by Yurdaydin, “experimental conditions do not necessarily mimic the situation in 
patients”29. And, we believe that the research effort being applied to further refinements in laboratory-based blood 
testing has been slow, especially in relationship to the importance of unmet clinical need. Finally, lab-based methods 
requiring phlebotomy will always be limited due the inconvenience of sample acquisition.
Figure 2. (a) Mean blood ammonia (μg/dL) change from baseline with 95% confidence interval by time 
(hours) for treatment groups: control (circle), 30 g protein (triangle), and 60 g protein (square). (b) Mean breath 
ammonia (ppb) change from baseline with 95% confidence interval by time (hour) for treatment groups: control 
(circle), 30 g protein (triangle), and 60 g protein (square).
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The totality of this experience further underscores the need for novel, fast, accurate, point-of-care measure-
ments easily tolerated by the test subject. We believe that the blood and breath methods used in this study are at 
least on par with the best blood and breath options available and have these key advantages. And importantly, 
there are many opportunities for future research. One approach would be to expand upon the present work by 
evaluating the impact, if any, of variables including individual factors (e.g., gender, age, race, body mass index, 
muscle mass), disease states (e.g., urea cycle disorders, cirrhosis), and oral challenges (e.g., protein and amino acid 
sources and compositions). Another approach would be to repeat a similar protocol and collect more metabolic 
data, such as standard urinary and blood markers for protein metabolism, to evaluate the sources of the ammonia 
increase and further validate the use of our ammonia measurement strategy.
Methods
Study Subjects. This study was approved by the Western Institutional Review Board. Participants were 
recruited via flyers and advertisements. All eligible participants provided written informed consent and all pro-
cedures followed the research protocols approved by the Western Institutional Review Board. Healthy volunteers, 
aged 18–40 years, without known periodontal, liver, or kidney disease or report of tobacco use, fasted 12 hours 
prior to presentation. Subjects with halitosis were excluded. Volunteers abstained from exercise the morning of 
the study and brushed their teeth at least 1 hour before arrival. Diabetics were excluded due to requirement that 
subjects present in the morning fasting. Subjects over 40 years old were excluded to minimize the risk of any 
subtle or undiagnosed metabolic condition.
Study Protocol. Subjects presented after an overnight fast to a breath research office in Hellertown, PA. The 
breath research office is a dedicated, private research space. No other medical or business activities occur at this 
site. All subjects completed a survey to attest to: tobacco, antibiotic, valproic acid, investigational drug use in the 
past 30 days, known severe periodontal disease, liver or kidney disease, diabetes, recent change in diet or unusual 
(especially high protein) diet. For each subject, informed consent was obtained and baseline data including age, 
height, weight, and gender were documented. Baseline blood and breath ammonia were measured. Subjects then 
ingested a control (0 g), moderate protein (30 g) or high protein (60 g) oral challenge. Repeat measurements for 
blood and breath ammonia were measured hourly for 5 hours.
The total testing time was 5.5 hours (30 minutes to complete intake, consent, and baseline testing, then 5 hours 
of post oral challenge testing). We chose 5 hours based on prior experience with high protein challenges and 
intended to capture maximum ammonia levels. No water, mouth rinse, tooth brushing, or chewing gum was 
permitted in the hour prior to the first breath collection. Water ingestion was allowed for 10 minutes after any one 
of the hourly breath collections.
Safety and tolerability was assessed throughout, and subjects were called the day following testing to ask about 
any adverse events.
The oral challenge for moderate or high protein testing days consisted of a commercially available shake 
(Premier Protein). Each shake (325 mL) contained 160 calories: 30 g protein, 3 g fat, and 5 g carbohydrate. For 
the moderate and high protein testing days, a subject consumed one or two shakes, respectively, for a total of 30 g 
or 60 g protein. Per the package label, this is a complete protein comprised of milk protein concentrate, calcium 
caseinate, and whey protein concentrate. For the control day, subjects consumed a commercially available elec-
trolyte drink (650 mL of Gatorade) containing zero protein; this was the same control used in an earlier study and 
was provided to allow for non-protein calorie intake in fasted subjects. All subjects completed the oral ingestion 
within 15 minutes.
All 22 subjects first completed the high protein testing day (60 g). This was to determine whether an ammonia 
response signal was detectable. Once confidence was established in this conclusion, then subjects were invited to 
complete the control (N = 12) and moderate (N = 10) protein test days.
Determination of Blood Ammonia. Blood ammonia was determined using the PocketChem BA blood 
ammonia analyzer obtained from Woodley Equipment (Lancashire, United Kingdom). PocketChem BA uses a 
microdiffusion method based on alkaline liberation of gaseous ammonia followed by passage through a spacer, 
and reaction with a bromocresol green indicator strip followed by colorimetric quantification of ammonia level. 
This analyzer uses a single wavelength (635 nm) reflection measurement method30. This small portable device 
uses 20 µL of blood collected with a disposable capillary tube and pipette. Alcohol wipes were used to cleanse the 
site thoroughly and a lancet was used to obtain the blood sample. Its methodology has been previously described 
and it favorably compared to other blood ammonia measurement methods5,31,32. The precision, linearity, repeata-
bility, and accuracy of the device have been evaluated33. It is used routinely in patient care and clinical research34,35 
around the world, though it is not licensed for patient use in the United States.
Determination of Breath Ammonia. Breath was determined using a prototype portable ammonia mon-
itor provided by Bedfont Scientific, Ltd (Kent, UK). The basis of the ammonia measurement is thermal oxidation 
of breath ammonia to nitric oxide (with a minimal amount of nitrogen dioxide) and water. This quantitative con-
version occurs in real-time. The thermal catalytic oxidation of breath ammonia to nitric oxide was first reported 
by Larson et al. in 197936. These investigators used a modified commercial environmental chemiluminescent 
nitric oxide analyzer (Model 14D, Thermo Electron Corp., Waltham, MA) to perform their studies. This approach 
to measure ammonia via thermal oxidation to nitric oxide has been adopted commercially and there are currently 
at least four instruments (Model 17 C, Thermo Electron Corporation, Franklin, MA; Model 17i Thermo Fisher 
Scientific, Waltham, MA; Model ML9842, Casella Monitor, Bedford, UK; and Model T201E, Enviro Technology 
Services, Gloucestershire, UK) that quantify environmental levels of ammonia using chemiluminescent detec-
tion of nitric oxide. The determination of environmental concentrations of ammonia using these commercial 
www.nature.com/scientificreports/
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instruments have been validated by the U.S. Environmental Protection Agency (EPA) in the Environmental 
Technology Verification (ETV) Program.
In the studies reported herein, the oxidation of ammonia is thermally cracked at 750 °C and a portion of 
oxidized breath is extracted at a constant rate (150 mL/min) and passed through three electrochemical sensors 
that analyze nitric oxide, oxygen and hydrogen. Monitoring nitric oxide with an electrochemical sensor instead 
of chemiluminescent monitor increased the portability of the resulting instrument. Additionally, the use of an 
electrochemical sensor for oxygen allows the end-tidal oxygen concentration to be monitored and the resulting 
breath ammonia data can be normalized to physiology. The plateaus for the exhalation of breath ammonia cor-
respond to stable plateau for lowest concentration of oxygen. This breath ammonia monitor adopts the accepted 
American Thoracic Society/European Respiratory Society (ATS/ERS) real-time protocol to measure the concen-
tration of nitric oxide (FeNO) that originates from the respiratory tract. The study subject is seated and asked to 
exhale into a tube containing a flow restrictor while maintaining a constant mouth pressure of 10 cm of H2O37. 
This protocol was followed to reduce any variability of endogenous breath nitric oxide since the selected mouth 
pressure ensures that the velum is blocked, thereby minimizing any contributions from the nose and sinuses to 
the levels of nitric oxide originating from the airways. The flow restrictor and selected mouth pressure produces 
the required exhalation flow rate of 50 mL/s. Controlled exhalation rate is used since the production of breath 
nitric oxide in the airways is flow dependent. Mouth pressure is displayed visually and is used to prompt the indi-
vidual to breathe at the defined constant rate of exhalation. The individual is encouraged to exhale at the constant 
exhalation rate to achieve a plateau in the nitric oxide (ammonia) versus time profile of at least 3 seconds. This sin-
gle breath maneuver is repeated until the measured nitric oxide (ammonia) plateaus fall within 10% of the mean 
value. Additionally, adopting the ATS/ERS protocol reduces the variability of the breath ammonia in longitudinal 
breath samples so intervention studies can be conducted.
The electrochemical sensors used in this prototype instrument are found in many commercial breath moni-
tors to measure nitric oxide, oxygen, and hydrogen. The addition of the hydrogen sensor allows the studies of the 
origin of ammonia to be performed. The monitor was calibrated daily and provides a reading in parts per billion 
(v/v). The accuracy of this prototype monitor was compared to an existing monitor developed by colleagues at 
Rice University based on the absorption of mid IR radiation6,7,38,39. Figure 3 illustrates a scatterplot of means 
of 3 duplicate samples obtained from 10 individuals by the Bedfont and Rice breath ammonia monitors. As 
described by the ATS/ERS recommendations for standardized procedures for the measurement of exhaled lower 
respiratory nitric oxide37, exhaled ammonia was calculated as the mean of three values. Of the 60 total samples, 
2 were excluded based on ATS/ERS protocol as a third measurement that did not agree within 10% of the other 
2 measurements. Correlation analysis of ammonia measurement (ppb) by Bedfont monitor versus Rice monitor 
is represented by regression line, Bedfont = −15 + 0.97 × Rice, with r2 of 0.97 and correlation coefficient of 0.98.
Breath and blood measurements were obtained within a period of 2 minutes.
Statistical Analysis. For each participant, blood and breath ammonia concentrations collected at 6 
time-points (at baseline then every hour for 5 hours) were used to calculate change from baseline, fold change, 
maximum concentration achieved, and area under the curve. For each of the three treatment groups: control (0 g), 
moderate protein (30 g), and high protein (60 g), the following parameters were calculated at each time point: 
mean ammonia concentration, mean change from baseline, and mean fold change. Differences in mean blood 
and breath ammonia amongst the three treatment groups were compared.
Longitudinal analysis was performed by linear mixed-effects model analysis (PROC MIXED, SAS, Cary, NC) 
and included fixed effects of baseline ammonia, treatment group (protein dose), time, and interaction of protein 
dose and time40. The inclusion of an interaction term allowed for the evaluation of the relationship between treat-
ment dose and elapsed time on the measured amount of ammonia. Time was treated as a categorical variable. 
Repeated measures and baseline values for each participant were treated as random effects. We evaluated multiple 
covariance structures for best fit based on relative goodness of fit of the covariance structures and designated 
Figure 3. Correlation analysis of ammonia measurement (ppb) by Bedfont monitor versus Rice monitor. Solid 
line represents regression line. Bedfont = −15 + 0.97 × Rice; r2 = 0.97; Pearson correlation coefficient = 0.98. 
N = 10; Graphed are means of three samples for each.
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compound symmetry as the covariance type. Pairwise comparisons were performed using estimate statements 
with contrasts from the longitudinal model.
All collected data were analyzed and no data were missing. All statistical analyses were conducted with SAS 
version 9.3 (SAS Institute, Inc., Cary, NC). Hypothesis tests were two-tailed and used a 5% significance level.
Data Availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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